Phase 3 Stomach Cancer Trial, Recruiting NCT03941561 Sponsor: Fudan University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT03941561
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old
  • People who have been confirmed by tissue testing to have primary stomach cancer (adenocarcinoma) at stage II
  • People who have had surgery that removed all visible cancer (R0 surgery) along with removal of nearby lymph nodes
  • People who have no other cancers present
  • People whose general health is rated as 0 or 1 on the ECOG scale (meaning largely or fully able to carry out daily activities), and who are expected to live more than 6 months
  • People whose blood counts, liver, kidney function, and heart trace (ECG) are within acceptable ranges (confirm with trial site for specific values)

Who may not be able to join:

  • People who are pregnant or breastfeeding, or who are unwilling to use contraception during chemotherapy
  • People whose stomach cancer is staged at I, III, or IV
  • People who were not able to have all cancer removed by surgery (R0 resection) or did not have a full D2 lymph node removal
  • People who have other serious uncontrolled conditions, such as other cancers or active infections
  • People with serious heart conditions, including heart failure, uncontrolled irregular heartbeat, unstable chest pain, previous heart attack, severe heart valve disease, or very high blood pressure that cannot be controlled
  • People with a known or suspected history of drug allergies (confirm with trial site)
  • People who are currently receiving other cancer treatments, including anti-cancer drugs, biological therapy, radiation, or immune-suppressing therapy within 4 weeks of joining
  • People who have had an organ transplant, require long-term immune-suppressing medication, or have an autoimmune disease
  • People whom the researchers believe would not be able to complete the full course of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dazhi Xu, PHD, MD, Fudan University

Phone: (+86) 020-87343737

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 January 2019
Est. completion
1 January 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov